<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33415820</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>17</Day></DateCompleted><DateRevised><Year>2021</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1440-1789</ISSN><JournalIssue CitedMedium="Internet"><Volume>41</Volume><Issue>2</Issue><PubDate><Year>2021</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Neuropathology : official journal of the Japanese Society of Neuropathology</Title><ISOAbbreviation>Neuropathology</ISOAbbreviation></Journal><ArticleTitle>An autopsy report of a familial amyotrophic lateral sclerosis case carrying VCP Arg487His mutation with a unique TDP-43 proteinopathy.</ArticleTitle><Pagination><StartPage>118</StartPage><EndPage>126</EndPage><MedlinePgn>118-126</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/neup.12710</ELocationID><Abstract><AbstractText>We here report an autopsy case of familial amyotrophic lateral sclerosis (ALS) with p.Arg487His mutation in the valosin-containing protein (VCP) gene (VCP), in which upper motor neurons (UMNs) were predominantly involved. Moreover, our patient developed symptoms of frontotemporal dementia later in life and pathologically exhibited numerous phosphorylated transactivation response DNA-binding protein of 43 kDa (p-TDP-43)-positive neuronal cytoplasmic inclusions and short dystrophic neurites with a few lentiform neuronal intranuclear inclusions, sharing the features of frontotemporal lobar degeneration with TDP-43 pathology type A pattern. A review of previous reports of ALS with VCP mutations suggests that our case is unique in terms of its UMN-predominant lesion pattern and distribution of p-TDP-43 pathology. Thus, this case report effectively expands the clinical and pathological phenotype of ALS in patients with a VCP mutation.</AbstractText><CopyrightInformation>&#xa9; 2021 Japanese Society of Neuropathology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Matsubara</LastName><ForeName>Tomoyasu</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-7559-8284</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Mifukai Vihara Hananosato Hospital, Hiroshima, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology and Neuropathology (The Brain Bank for Aging Research), Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Tokyo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Izumi</LastName><ForeName>Yuishin</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-3048-9041</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Mifukai Vihara Hananosato Hospital, Hiroshima, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oda</LastName><ForeName>Masaya</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mifukai Vihara Hananosato Hospital, Hiroshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takahashi</LastName><ForeName>Masatoshi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Shinko Hospital, Kobe, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maruyama</LastName><ForeName>Hirofumi</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-7613-8717</Identifier><AffiliationInfo><Affiliation>Department of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyamoto</LastName><ForeName>Ryosuke</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-6434-9541</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watanabe</LastName><ForeName>Chigusa</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, National Hospital Organization Hiroshima-Nishi Medical Center, Hiroshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tachiyama</LastName><ForeName>Yoshiro</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Clinical Laboratory, National Hospital Organization Hiroshima-Nishi Medical Center, Hiroshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morino</LastName><ForeName>Hiroyuki</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-5190-3547</Identifier><AffiliationInfo><Affiliation>Department of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kawakami</LastName><ForeName>Hideshi</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-1405-0901</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saito</LastName><ForeName>Yuko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neuropathology (The Brain Bank for Aging Research), Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murayama</LastName><ForeName>Shigeo</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-9709-5242</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Neuropathology (The Brain Bank for Aging Research), Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Tokyo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Molecular Research Center for Children's Mental Development (Brain Bank for Neurodevelopmental, Neurological and Psychiatric Disorders), United Graduate School of Child Development, Osaka University, Osaka, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>JP18dm0107103</GrantID><Agency>Japan Agency for Medical Research and Development</Agency><Country/></Grant><Grant><GrantID>JP16H06277</GrantID><Agency>the Research Committee of CNS Degenerative Diseases, Research on Policy Planning and Evaluation for Rare and Intractable Diseases, Health, Labor and Welfare Sciences Research Grants, the Ministry of Health, Labor and Welfare, Japan, MEXT/JSPS KAKENHI</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>01</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Neuropathology</MedlineTA><NlmUniqueID>9606526</NlmUniqueID><ISSNLinking>0919-6544</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.4.6</RegistryNumber><NameOfSubstance UI="C000614178">VCP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.4.6</RegistryNumber><NameOfSubstance UI="D000074405">Valosin Containing Protein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001344" MajorTopicYN="Y">Autopsy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057174" MajorTopicYN="N">Frontotemporal Lobar Degeneration</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045586" MajorTopicYN="N">Intranuclear Inclusion Bodies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057177" MajorTopicYN="N">TDP-43 Proteinopathies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000074405" MajorTopicYN="N">Valosin Containing Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">TDP-43</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">autopsy</Keyword><Keyword MajorTopicYN="N">frontotemporal lobar degeneration</Keyword><Keyword MajorTopicYN="N">valosin-containing protein (VCP)</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>5</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>1</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>1</Month><Day>8</Day><Hour>6</Hour><Minute>20</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33415820</ArticleId><ArticleId IdType="doi">10.1111/neup.12710</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Brown RH, Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med 2017; 377: 162-172.</Citation></Reference><Reference><Citation>Johnson JO, Mandrioli J, Benatar M et al. Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron 2010; 68: 857-864.</Citation></Reference><Reference><Citation>Watts GD, Wymer J, Kovach MJ et al. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat Genet 2004; 36: 377-381.</Citation></Reference><Reference><Citation>Koppers M, van Blitterswijk MM, Vlam L et al. VCP mutations in familial and sporadic amyotrophic lateral sclerosis. Neurobiol Aging 2012; 33: 837.e837-837.e813.</Citation></Reference><Reference><Citation>Ayaki T, Ito H, Fukushima H et al. Immunoreactivity of valosin-containing protein in sporadic amyotrophic lateral sclerosis and in a case of its novel mutant. Acta Neuropathol Commun 2014; 2: 172.</Citation></Reference><Reference><Citation>Inoue K, Fujimura H, Toyooka K, Hirano M, Nakamura Y, Sakoda S. An autopsy case of familial amyotrophic lateral sclerosis and dementia with p. R487H VCP gene mutation. Cogent Med 2018; 5: 1434925.</Citation></Reference><Reference><Citation>Surampalli A, Nalbandian A, Donkervoort S, Khare M, Wang A. A clinicopathologic case report of a female with Valosin-Containing Protein (VCP) gene mutation related disease. Int J Neurodegener Dis 2018; 1: 006.</Citation></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1: 293-299.</Citation></Reference><Reference><Citation>Geevasinga N, Loy CT, Menon P et al. Awaji criteria improves the diagnostic sensitivity in amyotrophic lateral sclerosis: A systematic review using individual patient data. Clin Neurophysiol 2016; 127: 2684-2691.</Citation></Reference><Reference><Citation>World Medical Association. World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA 2013; 310: 2191-2194.</Citation></Reference><Reference><Citation>Cleary EM, Pal S, Azam T et al. Improved PCR based methods for detecting C9orf72 hexanucleotide repeat expansions. Mol Cell Probes 2016; 30: 218-224.</Citation></Reference><Reference><Citation>Strong MJ, Abrahams S, Goldstein LH et al. Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria. Amyotroph Lateral Scler Frontotemporal Degener 2017; 18: 153-174.</Citation></Reference><Reference><Citation>Saito Y, Ruberu NN, Sawabe M et al. Staging of argyrophilic grains: An age-associated tauopathy. J Neuropathol Exp Neurol 2004; 63: 911-918.</Citation></Reference><Reference><Citation>Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239-259.</Citation></Reference><Reference><Citation>Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 2006; 112: 389-404.</Citation></Reference><Reference><Citation>Hirano M, Nakamura Y, Saigoh K et al. VCP gene analyses in Japanese patients with sporadic amyotrophic lateral sclerosis identify a new mutation. Neurobiol Aging 2015; 36: 1604.e1601-1604.e1606.</Citation></Reference><Reference><Citation>Mackenzie IR, Neumann M, Baborie A et al. A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol 2011; 122: 111-113.</Citation></Reference><Reference><Citation>Lee EB, Porta S, Michael Baer G et al. Expansion of the classification of FTLD-TDP: Distinct pathology associated with rapidly progressive frontotemporal degeneration. Acta Neuropathol 2017; 134: 65-78.</Citation></Reference><Reference><Citation>Neumann M, Mackenzie IR, Cairns NJ et al. TDP-43 in the ubiquitin pathology of frontotemporal dementia with VCP gene mutations. J Neuropathol Exp Neurol 2007; 66: 152-157.</Citation></Reference><Reference><Citation>van der Zee J, Pirici D, Van Langenhove T et al. Clinical heterogeneity in 3 unrelated families linked to VCP p.Arg159His. Neurology 2009; 73: 626-632.</Citation></Reference><Reference><Citation>Kimonis VE, Mehta SG, Fulchiero EC et al. Clinical studies in familial VCP myopathy associated with Paget disease of bone and frontotemporal dementia. Am J Med Genet A 2008; 146a: 745-757.</Citation></Reference><Reference><Citation>Peyer AK, Kinter J, Hench J et al. Novel valosin containing protein mutation in a Swiss family with hereditary inclusion body myopathy and dementia. Neuromuscul Disord 2013; 23: 149-154.</Citation></Reference><Reference><Citation>Spina S, Van Laar AD, Murrell JR et al. Phenotypic variability in three families with valosin-containing protein mutation. Eur J Neurol 2013; 20: 251-258.</Citation></Reference><Reference><Citation>DeJesus-Hernandez M, Desaro P, Johnston A et al. Novel p.Ile151Val mutation in VCP in a patient of African American descent with sporadic ALS. Neurology 2011; 77: 1102-1103.</Citation></Reference><Reference><Citation>Gonzalez-Perez P, Cirulli ET, Drory VE et al. Novel mutation in VCP gene causes atypical amyotrophic lateral sclerosis. Neurology 2012; 79: 2201-2208.</Citation></Reference><Reference><Citation>Abramzon Y, Johnson JO, Scholz SW et al. Valosin-containing protein (VCP) mutations in sporadic amyotrophic lateral sclerosis. Neurobiol Aging 2012; 33: 2231.e2231-2231.e2236.</Citation></Reference><Reference><Citation>Benatar M, Wuu J, Fernandez C et al. Motor neuron involvement in multisystem proteinopathy: Implications for ALS. Neurology 2013; 80: 1874-1880.</Citation></Reference><Reference><Citation>Segawa M, Hoshi A, Naruse H, Kuroda M, Bujo H, Ugawa Y. [A patient with familial amyotrophic lateral sclerosis associated with a new valosin-containing protein (VCP) gene mutation]. Rinsho Shinkeigaku 2015; 55: 914-920.</Citation></Reference><Reference><Citation>Abrahao A, Abath Neto O, Kok F et al. One family, one gene and three phenotypes: A novel VCP (valosin-containing protein) mutation associated with myopathy with rimmed vacuoles, amyotrophic lateral sclerosis and frontotemporal dementia. J Neurol Sci 2016; 368: 352-358.</Citation></Reference><Reference><Citation>Al-Obeidi E, Al-Tahan S, Surampalli A et al. Genotype-phenotype study in patients with valosin-containing protein mutations associated with multisystem proteinopathy. Clin Genet 2018; 93: 119-125.</Citation></Reference><Reference><Citation>Deng J, Wu W, Xie Z et al. Novel and recurrent mutations in a cohort of Chinese patients with young-onset amyotrophic lateral sclerosis. Front Neurosci 2019; 13: 1289.</Citation></Reference><Reference><Citation>Pensato V, Magri S, Bella ED et al. Sorting rare ALS genetic variants by targeted re-sequencing panel in Italian patients: OPTN, VCP, and SQSTM1 variants account for 3% of rare genetic forms. J Clin Med 2020; 9: 412.</Citation></Reference><Reference><Citation>Kotan D, &#xd6;z&#xf6;zen Ayas Z, Tunca C, Gungen BD, Ak&#xe7;imen F, Ba&#x15f;ak AN. Phenotypic and genotypic features of patients diagnosed with ALS in the city of Sakarya, Turkey. Acta Neurol Belg 2020 (Jul 15). https://doi.org/10.1007/s13760-020-01441-z [Epub ahead of print].</Citation></Reference><Reference><Citation>Schroder R, Watts GD, Mehta SG et al. Mutant valosin-containing protein causes a novel type of frontotemporal dementia. Ann Neurol 2005; 57: 457-461.</Citation></Reference><Reference><Citation>Haubenberger D, Bittner RE, Rauch-Shorny S et al. Inclusion body myopathy and Paget disease is linked to a novel mutation in the VCP gene. Neurology 2005; 65: 1304-1305.</Citation></Reference><Reference><Citation>Guyant-Marechal L, Laquerriere A, Duyckaerts C et al. Valosin-containing protein gene mutations: Clinical and neuropathologic features. Neurology 2006; 67: 644-651.</Citation></Reference><Reference><Citation>Forman MS, Mackenzie IR, Cairns NJ et al. Novel ubiquitin neuropathology in frontotemporal dementia with valosin-containing protein gene mutations. J Neuropathol Exp Neurol 2006; 65: 571-581.</Citation></Reference><Reference><Citation>Kaleem M, Zhao A, Hamshere M, Myers AJ. Identification of a novel valosin-containing protein polymorphism in late-onset Alzheimer's disease. Neurodegener Dis 2007; 4: 376-381.</Citation></Reference><Reference><Citation>Hubbers CU, Clemen CS, Kesper K et al. Pathological consequences of VCP mutations on human striated muscle. Brain 2007; 130: 381-393.</Citation></Reference><Reference><Citation>Krause S, Gohringer T, Walter MC et al. Brain imaging and neuropsychology in late-onset dementia due to a novel mutation (R93C) of valosin-containing protein. Clin Neuropathol 2007; 26: 232-240.</Citation></Reference><Reference><Citation>Watts GD, Thomasova D, Ramdeen SK et al. Novel VCP mutations in inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia. Clin Genet 2007; 72: 420-426.</Citation></Reference><Reference><Citation>Gidaro T, Modoni A, Sabatelli M, Tasca G, Broccolini A, Mirabella M. An Italian family with inclusion-body myopathy and frontotemporal dementia due to mutation in the VCP gene. Muscle Nerve 2008; 37: 111-114.</Citation></Reference><Reference><Citation>Viassolo V, Previtali SC, Schiatti E et al. Inclusion body myopathy, Paget's disease of the bone and frontotemporal dementia: Recurrence of the VCP R155H mutation in an Italian family and implications for genetic counselling. Clin Genet 2008; 74: 54-60.</Citation></Reference><Reference><Citation>Stojkovic T, Hammouda el H, Richard P et al. Clinical outcome in 19 French and Spanish patients with valosin-containing protein myopathy associated with Paget's disease of bone and frontotemporal dementia. Neuromuscul Disord 2009; 19: 316-323.</Citation></Reference><Reference><Citation>Vesa J, Su H, Watts GD et al. Valosin containing protein associated inclusion body myopathy: abnormal vacuolization, autophagy and cell fusion in myoblasts. Neuromuscul Disord 2009; 19: 766-772.</Citation></Reference><Reference><Citation>Djamshidian A, Schaefer J, Haubenberger D et al. A novel mutation in the VCP gene (G157R) in a German family with inclusion-body myopathy with Paget disease of bone and frontotemporal dementia. Muscle Nerve 2009; 39: 389-391.</Citation></Reference><Reference><Citation>Bersano A, Del Bo R, Lamperti C et al. Inclusion body myopathy and frontotemporal dementia caused by a novel VCP mutation. Neurobiol Aging 2009; 30: 752-758.</Citation></Reference><Reference><Citation>Kumar KR, Needham M, Mina K et al. Two Australian families with inclusion-body myopathy, Paget's disease of bone and frontotemporal dementia: Novel clinical and genetic findings. Neuromuscul Disord 2010; 20: 330-334.</Citation></Reference><Reference><Citation>Rohrer JD, Warren JD, Reiman D et al. A novel exon 2 I27V VCP variant is associated with dissimilar clinical syndromes. J Neurol 2011; 258: 1494-1496.</Citation></Reference><Reference><Citation>Fanganiello RD, Kimonis VE, Corte CC, Nitrini R, Passos-Bueno MR. A Brazilian family with hereditary inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia. Braz J Med Biol Res 2011; 44: 374-380.</Citation></Reference><Reference><Citation>Palmio J, Sandell S, Suominen T et al. Distinct distal myopathy phenotype caused by VCP gene mutation in a Finnish family. Neuromuscul Disord 2011; 21: 551-555.</Citation></Reference><Reference><Citation>Kim EJ, Park YE, Kim DS et al. Inclusion body myopathy with Paget disease of bone and frontotemporal dementia linked to VCP p.Arg155Cys in a Korean family. Arch Neurol 2011; 68: 787-796.</Citation></Reference><Reference><Citation>Shi Z, Hayashi YK, Mitsuhashi S et al. Characterization of the Asian myopathy patients with VCP mutations. Eur J Neurol 2012; 19: 501-509.</Citation></Reference><Reference><Citation>de Bot ST, Schelhaas HJ, Kamsteeg EJ, van de Warrenburg BP. Hereditary spastic paraplegia caused by a mutation in the VCP gene. Brain 2012; 135: e223; author reply e224.</Citation></Reference><Reference><Citation>Sacconi S, Camano P, de Greef JC et al. Patients with a phenotype consistent with facioscapulohumeral muscular dystrophy display genetic and epigenetic heterogeneity. J Med Genet 2012; 49: 41-46.</Citation></Reference><Reference><Citation>Mehta SG, Khare M, Ramani R et al. Genotype-phenotype studies of VCP-associated inclusion body myopathy with Paget disease of bone and/or frontotemporal dementia. Clin Genet 2013; 83: 422-431.</Citation></Reference><Reference><Citation>Gu JM, Ke YH, Yue H et al. A novel VCP mutation as the cause of atypical IBMPFD in a Chinese family. Bone 2013; 52: 9-16.</Citation></Reference><Reference><Citation>Jacquin A, Rouaud O, Soichot P et al. Psychiatric presentation of frontotemporal dementia associated with inclusion body myopathy due to the VCP mutation (R155H) in a French family. Case Rep Neurol 2013; 5: 187-194.</Citation></Reference><Reference><Citation>Komatsu J, Iwasa K, Yanase D, Yamada M. Inclusion body myopathy with Paget disease of bone and frontotemporal dementia associated with a novel G156S mutation in the VCP gene. Muscle Nerve 2013; 48: 995-996.</Citation></Reference><Reference><Citation>Igari R, Wada M, Sato H, Hayashi YK, Nishino I, Kato T. [A case of inclusion body myopathy with Paget's disease of bone and frontotemporal dementia (IBMPFD) showing clinical features of motor neuron disease]. Rinsho Shinkeigaku 2013; 53: 458-464.</Citation></Reference><Reference><Citation>Kamiyama T, Sengoku R, Sasaki M et al. [An advanced case of myopathy and dementia with a new mutation in the valosin-containing protein gene]. Rinsho Shinkeigaku 2013; 53: 465-469.</Citation></Reference><Reference><Citation>Segers K, Glibert G, Callebaut J, Kevers L, Alcan I, Dachy B. Involvement of peripheral and central nervous systems in a valosin-containing protein mutation. J Clin Neurol 2014; 10: 166-170.</Citation></Reference><Reference><Citation>Gonzalez MA, Feely SM, Speziani F et al. A novel mutation in VCP causes Charcot-Marie-Tooth Type 2 disease. Brain 2014; 137: 2897-2902.</Citation></Reference><Reference><Citation>Liewluck T, Milone M, Mauermann ML, Castro-Couch M, Cerhan JH, Murthy NS. A novel VCP mutation underlies scapuloperoneal muscular dystrophy and dropped head syndrome featuring lobulated fibers. Muscle Nerve 2014; 50: 295-299.</Citation></Reference><Reference><Citation>Weihl CC, Baloh RH, Lee Y et al. Targeted sequencing and identification of genetic variants in sporadic inclusion body myositis. Neuromuscul Disord 2015; 25: 289-296.</Citation></Reference><Reference><Citation>Jerath NU, Crockett CD, Moore SA et al. Rare manifestation of a c.290 C&gt;T, p.Gly97Glu VCP mutation. Case Rep Genet 2015; 2015: 239167.</Citation></Reference><Reference><Citation>Wang H, Wu S. Novel valosin containing protein mutation in a Swiss family with hereditary inclusion body myopathy and dementia. Neuromuscul Disord 2015; 25: 273.</Citation></Reference><Reference><Citation>Figueroa-Bonaparte S, Hudson J, Barresi R et al. Mutational spectrum and phenotypic variability of VCP-related neurological disease in the UK. J Neurol Neurosurg Psychiatry 2016; 87: 680-681.</Citation></Reference><Reference><Citation>van de Warrenburg BP, Schouten MI, de Bot ST et al. Clinical exome sequencing for cerebellar ataxia and spastic paraplegia uncovers novel gene-disease associations and unanticipated rare disorders. Eur J Hum Genet 2016; 24: 1460-1466.</Citation></Reference><Reference><Citation>Matsubara S, Shimizu T, Komori T, Mori-Yoshimura M, Minami N, Hayashi YK. Nuclear inclusions mimicking poly(A)-binding protein nuclear 1 inclusions in a case of inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia with a novel mutation in the valosin-containing protein gene. Neuromuscul Disord 2016; 26: 436-440.</Citation></Reference><Reference><Citation>Shi Z, Liu S, Xiang L et al. Frontotemporal dementia-related gene mutations in clinical dementia patients from a Chinese population. J Hum Genet 2016; 61: 1003-1008.</Citation></Reference><Reference><Citation>Kazamel M, Sorenson EJ, McEvoy KM et al. Clinical spectrum of valosin containing protein (VCP)-opathy. Muscle Nerve 2016; 54: 94-99.</Citation></Reference><Reference><Citation>Papadimas GK, Paraskevas GP, Zambelis T et al. The multifaceted clinical presentation of VCP-proteinopathy in a Greek family. Acta Myol 2017; 36: 203-206.</Citation></Reference><Reference><Citation>Inoue M, Iida A, Hayashi S et al. Two novel VCP missense variants identified in Japanese patients with multisystem proteinopathy. Hum Genome Var 2018; 5: 9.</Citation></Reference><Reference><Citation>Mengel D, Librizzi D, Schoser B et al. [Inclusion body myopathy, Paget's disease, and Fronto-temporal dementia: A VCP-related multi-systemic proteinopathy]. Fortschr Neurol Psychiatr 2018; 86: 434-438.</Citation></Reference><Reference><Citation>Shinjo SK, Oba-Shinjo SM, Lerario AM, Marie SKN. A Brazilian family with inclusion body myopathy associated with Paget's disease of bone and frontotemporal dementia linked to the VCP pGly97Glu mutation. Clin Rheumatol 2018; 37: 1129-1136.</Citation></Reference><Reference><Citation>Saracino D, Clot F, Camuzat A et al. Novel VCP mutations expand the mutational spectrum of frontotemporal dementia. Neurobiol Aging 2018; 72: 187.e111-187.e114.</Citation></Reference><Reference><Citation>Al-Tahan S, Al-Obeidi E, Yoshioka H et al. Novel valosin-containing protein mutations associated with multisystem proteinopathy. Neuromuscul Disord 2018; 28: 491-501.</Citation></Reference><Reference><Citation>Lucente G, Almendrote M, Ramos-Fransi A et al. A novel mutation in the valosin-containing-protein gene found in a Spanish family. J Neurol Sci 2018; 391: 112-113.</Citation></Reference><Reference><Citation>Wong TH, Pottier C, Hondius DC et al. Three VCP mutations in patients with frontotemporal dementia. J Alzheimers Dis 2018; 65: 1139-1146.</Citation></Reference><Reference><Citation>Falcao de Campos C, de Carvalho M. Distal myopathy and rapidly progressive dementia associated with a novel mutation in the VCP gene: Expanding inclusion body myopathy with early-onset Paget disease and frontotemporal dementia spectrum. J Clin Neurosci 2019; 64: 8-10.</Citation></Reference><Reference><Citation>Nomura E, Ohta Y, Sato K et al. A Japanese patient with a VCP mutation c. 290G&gt; A (p. G97E) presenting a rapid progressive respiratory failure. Neurol Clin Neurosci 2019; 7: 361-364.</Citation></Reference><Reference><Citation>Jerath NU. Resolving a multi-generational neuromuscular mystery in a family presenting with a variable Scapuloperoneal syndrome in a c.464G&gt;A, p.Arg155His VCP mutation. Case Rep Genet 2019; 2019: 2403024.</Citation></Reference><Reference><Citation>Guo X, Zhao Z, Shen H, Qi B, Li N, Hu J. VCP myopathy: A family with unusual clinical manifestations. Muscle Nerve 2019; 59: 365-369.</Citation></Reference><Reference><Citation>Pellerin D, Ellezam B, Korathanakhun P et al. Multisystem proteinopathy associated with a VCP G156S mutation in a French Canadian family. Can J Neurol Sci 2020; 47: 412-415.</Citation></Reference><Reference><Citation>Gite J, Milko E, Brady L, Baker SK. Phenotypic convergence in Charcot-Marie-Tooth 2Y with novel VCP mutation. Neuromuscul Disord 2020; 30: 232-235.</Citation></Reference><Reference><Citation>Doi Y, Atsuta N, Sobue G, Morita M, Nakano I. Prevalence and incidence of amyotrophic lateral sclerosis in Japan. J Epidemiol 2014; 24: 494-499.</Citation></Reference><Reference><Citation>Mehta P, Kaye W, Raymond J et al. Prevalence of amyotrophic lateral sclerosis - United States, 2015. MMWR Morb Mortal Wkly Rep 2018; 67: 1285-1289.</Citation></Reference><Reference><Citation>Global, regional, and national burden of motor neuron diseases 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2018; 17: 1083-1097.</Citation></Reference><Reference><Citation>Brooks BR. Natural history of ALS: Symptoms, strength, pulmonary function, and disability. Neurology 1996; 47: S71-S81; discussion S81-72.</Citation></Reference><Reference><Citation>Marin B, Boumediene F, Logroscino G et al. Variation in worldwide incidence of amyotrophic lateral sclerosis: A meta-analysis. Int J Epidemiol 2017; 46: 57-74.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>